RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Vivoryon Therapeutics Stock

Vivoryon Therapeutics P/E 2024

Vivoryon Therapeutics P/E

-2.63

Ticker

VVY.AS

ISIN

NL00150002Q7

WKN

A2QJV6

As of Dec 18, 2024, Vivoryon Therapeutics's P/E ratio was -2.63, a -79.21% change from the -12.65 P/E ratio recorded in the previous year.

The Vivoryon Therapeutics P/E history

Vivoryon Therapeutics Aktienanalyse

What does Vivoryon Therapeutics do?

Vivoryon Therapeutics NV is a biopharmaceutical company specializing in the development of drugs for the treatment of Alzheimer's and other neurodegenerative diseases. The company was founded in 2016 in Leuven, Belgium and is headquartered in Heidelberg, Germany. Vivoryon Therapeutics has a history dating back to 2005 when it was supported by EFPIA-AIM. The company has since gone through several successful financing rounds to advance its research and development efforts. Its business model is based on the discovery and development of therapeutics with a new chemical approach to treating Alzheimer's and other neurodegenerative diseases. Vivoryon Therapeutics is currently involved in three different therapy areas: small molecule blockers, epigenetics, and big data analytics and telemetry technologies. The company is also developing a drug known as PQ912, which has the potential to slow down the progression of Alzheimer's disease. Vivoryon Therapeutics has partnerships and collaborations with various institutions to further its research and development programs. Overall, the company has the potential to revolutionize the treatment of Alzheimer's and other neurodegenerative diseases through its innovative efforts and collaborations. Vivoryon Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Vivoryon Therapeutics's P/E Ratio

The Price to Earnings (P/E) Ratio of Vivoryon Therapeutics is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Vivoryon Therapeutics's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Vivoryon Therapeutics is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Vivoryon Therapeutics’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Vivoryon Therapeutics stock

What is the price-to-earnings ratio of Vivoryon Therapeutics?

The price-earnings ratio of Vivoryon Therapeutics is currently -2.63.

How has the price-earnings ratio of Vivoryon Therapeutics changed compared to last year?

The price-to-earnings ratio of Vivoryon Therapeutics has increased by -79.21% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Vivoryon Therapeutics high compared to other companies?

Yes, the price-to-earnings ratio of Vivoryon Therapeutics is high compared to other companies.

How does an increase in the price-earnings ratio of Vivoryon Therapeutics affect the company?

An increase in the price-earnings ratio of Vivoryon Therapeutics would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Vivoryon Therapeutics affect the company?

A decrease in the price-earnings ratio of Vivoryon Therapeutics would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Vivoryon Therapeutics?

Some factors that influence the price-earnings ratio of Vivoryon Therapeutics are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Vivoryon Therapeutics pay?

Over the past 12 months, Vivoryon Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Vivoryon Therapeutics is expected to pay a dividend of 0 EUR.

What is the dividend yield of Vivoryon Therapeutics?

The current dividend yield of Vivoryon Therapeutics is .

When does Vivoryon Therapeutics pay dividends?

Vivoryon Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Vivoryon Therapeutics?

Vivoryon Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Vivoryon Therapeutics?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Vivoryon Therapeutics located?

Vivoryon Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Vivoryon Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Vivoryon Therapeutics from 12/18/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 12/18/2024.

When did Vivoryon Therapeutics pay the last dividend?

The last dividend was paid out on 12/18/2024.

What was the dividend of Vivoryon Therapeutics in the year 2023?

In the year 2023, Vivoryon Therapeutics distributed 0 EUR as dividends.

In which currency does Vivoryon Therapeutics pay out the dividend?

The dividends of Vivoryon Therapeutics are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Vivoryon Therapeutics

Our stock analysis for Vivoryon Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Vivoryon Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.